Table 4a. Tumor load between patients with wild-type and variant genotypes concerning the CYP2B6*9 (G516T) variant following cyclophosphamide chemotherapy.
| Parameter | GG | GT + TT | p-value | |
|---|---|---|---|---|
| n = 40 | n = 51 | |||
| Lymph nodes♦ | Non-enlarged | 32 (80%) | 19 (37%) | <0.001* |
| Enlarged | 8 (20%) | 32 (63%) | ||
| Spleen♦ | Non-enlarged | 31 (77.5%) | 20 (39%) | <0.001* |
| Enlarged | 9 (22.5%) | 31 (61%) | ||
| Liver | Non-enlarged | 33 (82.5%) | 20 (39%) | <0.001* |
| Enlarged | 7 (17.5%) | 31 (61%) | ||
| B-symptoms | Absent | 37 (92.5%) | 41 (80%) | =0.10 |
| Present | 3 (7.5%) | 10 (20%) | ||
| Lymphocytes (×109/L) | Median (range) | 3.9 (0.5–165) | 57.3 (30–177) | <0.001* |
| Marrow infiltration (%) | Median (range) | 13 (4–88) | 66 (42–89) | <0.001* |
Note: Chi-square and Mann-Whitney U tests were used. *: statistically significant (if p < 0.05), ♦: enlarged lymph node if >1.5 cm and the enlarged spleen if >13 cm.